Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy
- PMID: 26280815
- PMCID: PMC5657150
- DOI: 10.1002/cncr.29611
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy
Abstract
Background: In men with clinically localized prostate cancer who have undergone at least 1 previous negative biopsy and have elevated serum prostate-specific antigen (PSA) levels, long-term health outcomes associated with the assessment of urinary prostate cancer antigen 3 (PCA3) and the transmembrane protease, serine 2 (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) gene fusion (T2:ERG) have not been investigated previously in relation to the decision to recommend a repeat biopsy.
Methods: The authors performed a decision analysis using a decision tree for men with elevated PSA levels. The probability of cancer was estimated using the Prostate Cancer Prevention Trial Risk Calculator (version 2.0). The use of PSA alone was compared with the use of PCA3 and T2:ERG scores, with each evaluated independently, in combination with PSA to trigger a repeat biopsy. When PCA3 and T2:ERG score evaluations were used, predefined thresholds were established to determine whether the patient should undergo a repeat biopsy. Biopsy outcomes were defined as either positive (with a Gleason score of <7, 7, or >7) or negative. Probabilities and estimates of 10-year overall survival and 15-year cancer-specific survival were derived from previous studies and a literature review. Outcomes were defined as age-dependent and Gleason score-dependent 10-year overall and 15-year cancer-specific survival rates and the percentage of biopsies avoided.
Results: Incorporating the PCA3 score (biopsy threshold, 25; generated based on the urine PCA3 level normalized to the amount of PSA messenger RNA) or the T2:ERG score (biopsy threshold, 10; based on the urine T2:ERG level normalized to the amount of PSA messenger RNA) into the decision to recommend repeat biopsy would have avoided 55.4% or 64.7% of repeat biopsies for the base-case patient, respectively, and changes in the 10-year survival rate were only 0.93% or 1.41%, respectively. Multi-way sensitivity analyses suggested that these results were robust with respect to the model parameters.
Conclusions: The use of PCA3 or T2:ERG testing for repeat biopsy decisions can substantially reduce the number of biopsies without significantly affecting 10-year survival.
Keywords: TMPRSS2-ERG; prostate cancer; prostate cancer antigen 3; repeat biopsy; serine 2-ETS-related gene fusion; survival; transmembrane protease; urinary biomarkers.
© 2015 American Cancer Society.
Conflict of interest statement
Comment in
-
Prostate cancer: Urinary PCA3 and TMPRSS2:ERG reduce the need for repeat biopsy.Nat Rev Urol. 2015 Oct;12(10):536. doi: 10.1038/nrurol.2015.221. Epub 2015 Sep 8. Nat Rev Urol. 2015. PMID: 26345208 No abstract available.
Similar articles
-
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15. Eur Urol. 2014. PMID: 23201468
-
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16. Eur Urol. 2016. PMID: 25985884 Free PMC article.
-
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20. Prostate. 2013. PMID: 22821767
-
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.Int J Mol Sci. 2016 Oct 26;17(11):1784. doi: 10.3390/ijms17111784. Int J Mol Sci. 2016. PMID: 27792187 Free PMC article. Review.
-
Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.Clin Genitourin Cancer. 2016 Apr;14(2):117-21. doi: 10.1016/j.clgc.2015.12.001. Epub 2015 Dec 17. Clin Genitourin Cancer. 2016. PMID: 26774207 Review.
Cited by
-
Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a030601. doi: 10.1101/cshperspect.a030601. Cold Spring Harb Perspect Med. 2018. PMID: 29311125 Free PMC article. Review.
-
Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis.Cancers (Basel). 2021 Jul 5;13(13):3373. doi: 10.3390/cancers13133373. Cancers (Basel). 2021. PMID: 34282798 Free PMC article. Review.
-
The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer.Oncotarget. 2019 Nov 12;10(61):6589-6603. doi: 10.18632/oncotarget.27284. eCollection 2019 Nov 12. Oncotarget. 2019. PMID: 31762940 Free PMC article.
-
MyProstateScore in men considering repeat biopsy: validation of a simple testing approach.Prostate Cancer Prostatic Dis. 2023 Sep;26(3):563-567. doi: 10.1038/s41391-022-00633-3. Epub 2022 Dec 30. Prostate Cancer Prostatic Dis. 2023. PMID: 36585434 Free PMC article.
-
Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs.Res Rep Urol. 2023 Jun 26;15:243-259. doi: 10.2147/RRU.S385257. eCollection 2023. Res Rep Urol. 2023. PMID: 37396015 Free PMC article. Review.
References
-
- Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529. - PubMed
-
- Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta. 2002;315:71. - PubMed
-
- Raja J, Ramachandran N, Munneke G, et al. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol. 2006;61:142. - PubMed
-
- Seitz C, Palermo S, Djavan B. Prostate biopsy. Minerva Urol Nefrol. 2003;55:205. - PubMed
-
- Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous